Key Highlights
- Net loss for the third quarter of 2026 was USD 2.6 million, or USD 0.50 per share, compared with USD 2.9 million, or USD 0.65 per share, a year earlier, according to the principal financial officer.
- Cash and cash equivalents were USD 7.5 million at quarter end against USD 8.8 million at June 30, while cash used in operations fell to about USD 1.3 million from about USD 2.1 million in the second quarter.
- General and administrative expense fell 44% to USD 1.0 million on lower professional fees and stock compensation, while Research and Development rose to USD 1.8 million from USD 1.1 million.
- The company recognized its first pre-commercial product revenue, from agenT-797 supplied to named patients outside the United States, though management gave no dollar amount on the call.
First Revenue Arrives Through a Named Patient Program
MiNK Therapeutics (NASDAQ:INKT) reported third-quarter 2026 results on a call held November 11, 2026. Management said it recognized its first pre-commercial product revenue from agenT-797, an off-the-shelf cell therapy, supplied on a paid per-patient basis under a named patient Import pathway now open in multiple countries outside the United States. Each request starts with a treating physician and is authorized case by case by regulators, because the therapy remains investigational. Management said Demand will vary from quarter to quarter on physician requests and regulatory authorizations, and the amount of revenue was not stated on the call.
Cost Cuts Narrow the Loss but Cash Is Under USD 8 Million
The net loss narrowed to USD 2.6 million, or USD 0.50 per share, with general and administrative expense down 44% to USD 1.0 million. Research and development rose to USD 1.8 million on the randomized Phase 2 study and translational work. Cash of USD 7.5 million compares with USD 8.8 million at June 30, and about USD 1.3 million was used in operations, the lowest quarter of the year. Management said it will strengthen the Balance Sheet through partnerships, licensing, non-dilutive funding and Equity or debt financing, with funding the randomized study through its readout as the priority.
ARDS Trial, FDA Meeting and ARPA-H Selection
The randomized, placebo-controlled Phase 2 trial in acute lung injury is enrolling in Lviv, Ukraine, and management expects U.S. dosing before year-end. It plans an FDA meeting before year-end on an adaptive Phase 2b/3 design that would enroll about 124 patients and could expand to as many as 300. A comparative readout is expected in 2027, with the chief executive pointing to around the third quarter. In September the therapy was selected for the ARPA-H BioStabilization Systems program, which commits up to USD 87 million over four years, with MiNK taking part on a fixed-fee basis. A graft-versus-host disease study is expected to dose its first patient by December.
Where Things Stand
MiNK Therapeutics (NASDAQ:INKT) is unlikely to reach a lung trial readout on USD 7.5 million alone, and management itself said it will seek more capital. Quarterly cash use of about USD 1.3 million shows the spending cuts are working, yet the balance sheet remains small against a trial that reads out in 2027. Revenue from named patients is a first step, not yet a measurable contributor. Next markers are the FDA meeting, first U.S. dosing, conference data management said it expects to present in the first half of 2027, and any financing or partnership.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...